T he type 1 Ang II receptors, AT 1A -R and AT 1B -R, undergo rapid homologous downregulation on exposure to Ang II. [1] [2] [3] Multiple mechanisms, such as desensitization and concurrent internalization, seem to be involved in this response to maintain cellular homeostasis. The mechanism of desensitization is complex; however, receptor phosphorylation seems to be an initial and major step. Extensive mutagenesis studies on the ␤ 2 -adrenergic receptor revealed that phosphorylation of two Ser residues located on the third cytoplasmic loop and in the proximal portion of the cytoplasmic tail by protein kinase A is involved in the heterologous desensitization of the receptor, whereas agonist-induced homologous desensitization requires phosphorylation of many Ser/Thr residues in the distal portion of the receptor cytoplasmic tail by ␤-ARK. Phosphorylation of the cytoplasmic tail by ␤-ARK induces arrestin-like protein binding to the receptor, which has been proposed to block fully the physical coupling of receptor to G s protein and adenylyl cyclase. 4 This indicates multiple mechanisms for desensitization by phosphorylation. In the G q/11 -coupled AT 1A -R, the desensitization mechanisms are not well understood. Although the receptor phosphorylation is associated with desensitization, whether they are causally related is not clear. 3 Conflicting views exist as to the sites of phosphorylation. Thomas et al 5 proposed that the second cytoplasmic loop may be the site of phosphorylation responsible for AT 1A -R desensitization, whereas Balmforth et al 6 reported observations indicating involvement of a long cytoplasmic tail in the receptor desensitization, without identifying specific domains.
The desensitization of the AT 1 receptor was shown to occur independent of the receptor internalization in rat cardiomyocytes. 1 We were able to show that the desensitization of AT 1B -R can occur even if receptor internalization is inhibited and concluded that the two phenomena are distinct receptor functions even though they occur concurrently. 2 Although AT 1A -R and AT 1B -R share a high degree of structural homology, they have some considerable differences in the cytoplasmic tail region, particularly in positions of Ser/Thr residues. Du et al 7 have recently reported that AT 1A -R and AT 1B -R are regulated in opposite directions on low salt feeding. Since AT 1A -R is the dominant subtype of the AT 1 receptor in most of tissues, except for the adrenal and pituitary glands, determination of the mechanism of its desensitization has long been overdue.
Since we have been able to obtain cells expressing AT 1A -R at a high level, which will enable us to quantify the downregulation of the receptor and its functions, we have performed studies directed to the delineation of the receptor domains involved in the desensitization using various mutants of AT 1A -R and a thioredoxin fusion protein containing the entire carboxyl-terminal region of the receptor. To gain insight into the type of kinases involved in this process, we have also applied reagents that stimulate or inhibit PKC and GRKs. We have obtained evidence that the proximal portion (K 310 to L 317 ) of the receptor cytoplasmic tail is involved in the AT 1A -R coupling to G q and that the potential Ser/Thr phosphorylation sites located between S 328 and S 347 in the cytoplasmic tail play a critical role in the agonist-and phorbol ester (PMA)-induced desensitization. Finally, the type and role of protein kinases involved in agonist-induced desensitization of the AT 1A -R were examined. 1 Ile 8 ]Ang II were obtained from Peninsula Laboratories; the nonpeptide receptor antagonist losartan and PD124319 were obtained from Research Biochemical Inc; PVDF membranes were purchased from Millipore; GF109203X, W-7, and H-89 were purchased from Calbiochem; the restriction enzymes and calcium phosphate transfection kits were obtained from Promega; expression vector pRc/CMV and the thiofusion expression system were purchased from Invitrogen Corp; PKC (␣, ␤, and ␥), Src kinase, Src kinase substrate peptide, and PKC assay kits were from Upstate Biotechnology Inc; and the polyclonal antibodies against GRKs and PLCs were from Santa Cruz. All other chemicals were purchased from Sigma Chemical Co.
Materials and Methods

Materials
Stable Expression of WT and Truncated AT 1A -R
The entire coding region of rat kidney AT 1A -R cDNA (an open reading frame encoding 359 amino acid residues) was subcloned into the BstXI site of the pRc/CMV expression vector. Truncated mutants lacking carboxyl-terminal segments of varying lengths were prepared by inserting a stop codon. Sites of truncation are shown in Fig 1. The mutated DNA was confirmed by dideoxynucleotide sequencing using appropriate primers, as described by Sanger et al, 8 and subcloned into the expression vector pRc/CMV. CHO-K1 cells were grown in Ham's F-12 medium containing 10% fetal calf serum at 37°C in a humidified incubator with 5% CO 2 . At 50% confluence, CHO cells were transfected with WT or truncated AT 1A -R plasmid DNA using a calcium phosphate precipitation/glycerol shock procedure previously described. 2 After selection in G418 (500 g/mL), resistant colonies were isolated, amplified, and screened for receptor expression by radioligand binding assay. Cells were propagated in flasks with Ham's F-12 medium supplemented with 10% fetal calf serum under a selection pressure of 150 g/mL G418 in an atmosphere of 95% air and 5% CO 2 at 37°C.
Radioligand Binding Assay
Monoiodinated 125 I-[Sar, 1 Ile 8 ]Ang II was prepared by the lactoperoxidase method 9 and purified by reversed-phase HPLC as described previously 10 except that a 0% to 80% acetonitrile gradient was applied for 60 minutes with a flow rate of 1.0 mL/min. Binding studies were performed with cells at or near confluence essentially as described previously. 2 The assay buffer consisted of 50 mmol/L Tris-HCl, pH 7.4, 100 mmol/L NaCl, 5 mmol/L MgCl 2 , 0.25% BSA, and 0.5 mg/mL bacitracin. For determination of receptor affinity and density, competition binding studies were performed in the presence of 50 pmol/L 125 I-[Sar, 1 Ile 8 ]Ang II and increasing concentrations of unlabeled ligands (10 Ϫ12 to 10 Ϫ6 mol/L). For measurement of the surface receptor binding capacity, the cells were pretreated as indicated and then incubated in the presence of 100 nmol/L Ang II for the indicated period at 37°C. Cells were then washed with ice-cold 50 mmol/L glycine and 150 mmol/L NaCl, pH 3.0, for 5 minutes at 4°C, followed by two saline washes. The binding studies were performed at near-saturating conditions with 2 nmol/L 125 I-[Sar, 1 Ile 8 ]Ang II for 3 hours at 4°C.
Measurement of IP 3 Production
Cells were subcultured into 12-well dishes and were exposed to Ang II at or near confluence; the treatment was stopped by the addition of 1/5 vol of 100% ice-cold trichloroacetic acid to the plates. The cells were then harvested by scraping and transferred to polypropylene tubes. The cell extract was vortexed thoroughly and then centrifuged for 10 minutes at 6000g at 4°C. The supernatant was removed and warmed to room temperature for 15 minutes. Levels of IP 3 in each supernatant were determined by use of a radioimmunoassay kit from Dupont NEN following the manufacturer's instructions.
Permeabilization of CHO Cells
CHO cells bearing AT 1A -R at subconfluence in 12-well plates were washed twice with prewarmed calcium-free PBS and then washed twice with KG buffer (mmol/L: KCl 120, NaCl 30, MgCl 2 2.5, K 2 HPO 4 1, PIPES 10, EGTA 2, and CaCl 2 0.5, pH 7.2). Cells were then incubated for 30 seconds with 0.0075% digitonin at room temperature in KG-A buffer (KG buffer supplemented with 5 mmol/L glucose and 2 mmol/L ATP), followed by three washes with KG buffer. Under this condition, Ͼ95% of the cells were permeabilized as assessed by staining with trypan blue. After permeabilization, the cells were loaded with mastoparan or low molecular weight heparin (average molecular weight, 3000) by incubation with 100 mol/L mastoparan or 10 mol/L heparin for 15 minutes in KG-A buffer at 37°C, respectively.
Selected Abbreviations and Acronyms
Ang II ϭ angiotensin II ␤-ARK ϭ ␤ 2 -adrenergic receptor kinase AT 1A -R, AT 1B -R ϭ AT 1A 
Desensitization of Receptors
Studies were performed essentially as described previously. 2 In brief, the mastoparan-or heparin-loaded cells, or cells pretreated with chemicals as indicated, were incubated with or without 100 nmol/L Ang II in serum-free medium for indicated periods at 37°C. The reaction was stopped by washing the cells with 150 mmol/L NaCl/ 50 mmol/L glycine (pH 3.0) for 5 minutes at 4°C and with prewarmed PBS twice. For measurement of the IP 3 level in response to Ang II, the cells were again stimulated with Ang II (100 nmol/L), and 15 seconds later the IP 3 mass was assayed as described above.
Preparation of the Bacterial Thioredoxin-AT 1A Fusion Protein
A region of the rat AT 1A -R cDNA encoding the entire cytoplasmic tail (N 295 to E 359 ) was amplified by polymerase chain reaction and inserted into pBluescript KS(ϩ) TA vector, and DNA was sequenced. Then, the BamHI-SalI fragment was cut and inserted into the same sites of the thiofusion expression plasmid pTrxFus vector in the frame. Induction of pTrxFus-AT 1A -transformed Escherichia coli with tryptophan (100 g/mL) resulted in the production of a fusion protein of Ϸ19 kD (11.6 kD of thioredoxin plus Ϸ7.5 kD for N 295 to E 359 ). The fusion protein was purified with activated ThioBond resin (Invitrogen Corp) according to manufacturer's protocols.
Preparation of Cell Fractions and Western Blotting
Serum-starved cells were washed twice with PBS and stimulated with 100 nmol/L Ang II for the indicated periods. Then, the cells were washed with ice-cold PBS and scraped into 0.5 mL per dish of lysis buffer (10 mmol/L Tris-HCl, pH 7.4, 5 mmol/L EDTA, 0.1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L benzamidine, and 10 g/mL leupeptin and aprotinin). The cells were allowed to swell for 10 to 15 minutes and were then homogenized three times (30 seconds each) in a Polytron homogenizer (Brinkmann). Unbroken cells and cell nuclei were sedimented at 800g for 3 minutes and discarded. The plasma membranes were collected by centrifugation at 48 000g for 20 minutes and resuspended in lysis buffer. The supernatant, representing the cytosolic fraction, was centrifuged at 100 000g for 60 minutes.
Preparations were kept at Ϫ80°C and used for Western blot or kinase assay. Samples containing equal amounts of protein (50 to 100 g) were separated by 7.5% SDS-PAGE gels and transferred to PVDF membranes. Membranes were probed with 0.3 to 0.5 g/mL GRK polyclonal antibodies, and immunoreactive bands were visualized with the enhanced chemiluminescence detection system (New England Biolabs). For Western blotting of PLCs, CHO/AT 1A -R cells or VSMCs were lysed on ice in lysis buffer containing 1% Triton X-100. The detergent-lysed cell extracts were separated by 7.5% SDS-PAGE gels and subjected to Western blotting with PLC polyclonal antibodies as described above.
In Vitro Phosphorylation of Thioredoxin-AT 1A Fusion Protein
For measuring the PKC-dependent or Src kinase-dependent phosphorylation of thioredoxin-AT 1A fusion protein, purified thioredoxin-AT 1A fusion protein (5 g 32 P]ATP for 30 minutes at 30°C. The reaction was terminated by the addition of 1 mL ice-cold TE buffer (mmol/L: Tris-HCl 10 and EDTA 10, pH 7.4). ThioBond resin was added, collected by centrifugation (13 000g for 10 seconds), and washed four times with 1 mL of TE buffer. Bound fusion protein was dissociated by boiling in 1ϫ SDS-PAGE sample buffer. Proteins were resolved by 15% SDS-PAGE. Gels were then dried and analyzed by autoradiography.
Results
Desensitization of the AT 1A -R-Mediated IP 3 Formation
To investigate mechanisms underlying the agonist-induced desensitization of AT 1A -R, we expressed cloned rat WT AT 1A -R in 12 Western blot analysis demonstrated that PLC ␤1 (150 kD), PLC ␤3 (150 kD), and PLC␥ 1 (145 kD) were clearly detected in CHO cells expressing high levels of WT AT 1A -R (CHO/AT 1A -R cells), whereas only PLC ␤3 and PLC␥ 1 were detected in VSMCs (Fig 2) . To determine whether Ang II-induced formation of IP 3 was sensitive to the tyrosine kinase inhibitors or calmodulin inhibitor W-7, we measured IP 3 response to Ang II in CHO/AT 1A -R cells with three different tyrosine inhibitors (genistein, herbimycin-A, and lavendustin A) or W-7. The results (not presented) showed that neither compound affected the IP 3 response to Ang II in intact cells. This observation suggests that the IP 3 response to Ang II in CHO/ AT 1A -R cells is probably mediated by PLC ␤1 through G q/11 .
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To ascertain whether agonist-induced desensitization of AT 1A -R expressed in CHO cells occurs, we determined the effect of a pretreatment with Ang II on the subsequent maximal Ang II-stimulated IP 3 formation. The pretreatment with Ang II resulted in a subsequent attenuation of IP 3 response to Ang II. By varying the time of preexposure to the agonist from 1 minute to 30 minutes, we found that Ang II rapidly induced receptor desensitization as early as 1 minute (PϽ.05), with complete desensitization observed by pretreatment for 15 minutes (Fig 3A) . Attenuation of IP 3 production was maximal when cells were pretreated with 10 to 100 nmol/L Ang II, and half-maximal effects were observed after pretreatment with Ϸ3 nmol/L Ang II (Fig 3B) .
Involvement of GRKs in Agonist-Induced Homologous Desensitization of AT 1A -R
We and others 2, 13, 14 have shown that PKC is involved in the heterologous desensitization of the AT 1 receptor. Treatment of CHO/AT 1A -R cells with PMA (100 nmol/L) for 10 minutes completely abolished receptor-mediated production of IP 3 with no effect on the basal level of IP 3 (Fig 4) . This effect of PMA was completely antagonized by pretreating the cells with 10 mol/L of a newly tested in vitro and in vivo nontoxic PKC-specific inhibitor, GF109203X 15 (Fig 4) . Consistent with the effects of the PKC inhibitor, downregulation of PKC by overnight incubation with PMA (1 mol/L) 16 completely blocked the desensitization of the AT 1A -R by PMA (data not shown). Like AT 1B -R, desensitization of AT 1A -R by a low Ang II concentration (1 nmol/L) was abolished by GF109203X, whereas the desensitizing effect at a high agonist concentration (100 nmol/L) was only partially prevented by GF109203X (Fig 4) . The partial attenuation was seen even at a high dose of this compound (20 mol/L) or with PKC depletion by overnight treatment with 1 mol/L PMA (data not shown). These results suggests that a PKC-independent pathway, probably involving GRKs, contributes to the homologous desensitization of the AT 1A -R in transfected CHO cells.
We then studied the role of GRKs in agonist-induced homologous desensitization of AT 1A -R. Mastoparan, a wasp venom peptide, has been known to mimic the agonist-bound (active form) GPCRs and activate GRKs. 17, 18 Incubation of permeabilized CHO/AT 1A -R cells with 100 mol/L mastoparan for 10 minutes completely abolished the receptormediated IP 3 response to Ang II (Fig 5) . On the other hand, pretreatment of the permeabilized cells with 10 mol/L heparin, a potent GRK inhibitor, 19, 20 for 20 minutes largely prevented the Ang II-induced desensitization of the AT 1A -Rmediated IP 3 response. The pretreatment with heparin decreased the basal level of IP 3 only slightly (Fig 5) .
These results indicate that PKC plays a major role in the heterologous desensitization of AT 1A -R and that a heparinsensitive GRK(s) may be involved in the agonist-induced homologous desensitization of the receptor in transfected CHO cells.
Impaired Heterologous or Homologous Desensitization of Truncated Mutants of AT 1A -R
To address the possible role of the cytoplasmic tail in the regulation of AT 1A -R, we constructed truncated mutants of AT 1A -R and stably expressed them in CHO cells. As shown in Fig 1, T310 and T318 truncation removes all Ser/Thr residues, including three potential PKC phosphorylation sites in the cytoplasmic tail of the AT 1A -R; T328 truncation removes all but the Ser 326 ; and T348 truncation removes a potentially farnesylated cysteine and two Ser residues in the tail, including one PKC phosphorylation site, S 348 AK. Clonal, stably transfected cells expressing T310, T318, or T348 AT 1A -R were prepared and matched with CHO/AT 1A -R cells expressing WT AT 1A -R at a high level. Cells expressing the T328 receptor were compared with cells bearing low levels of WT AT 1A -R (Table) . As shown in the 3 formation in response to Ang II demonstrated that truncated mutants (T318, T328, and T348) of AT 1A -R couple with effector PLC with an efficiency similar to that of full-length receptors. By contrast, the IP 3 formation on Ang II stimulation was barely detected in cells expressing high levels of truncated mutant T310, indicating the region between K 310 and L 317 in the cytoplasmic tail of the AT 1A -R that is involved in the receptor coupling to G q protein (Table) .
As shown in Fig 6 , pretreatment of cells expressing WT AT 1A -R or mutant T348 with 100 nmol/L Ang II abolished the IP 3 response of the cells to a subsequent maximal stimulation with Ang II. By contrast, the Ang II-induced attenuation of the IP 3 response was markedly impaired in both cell clones expressing T318 or T328 AT 1A -R, indicating that potential Ser/Thr phosphorylation sites located between S 328 and S 347 in the cytoplasmic tail are important for the agonist-induced desensitization. In addition to the impaired agonist-induced desensitization, the PMA-dependent heterologous desensitization of the receptor was also dramatically impaired in the truncated mutants T318 and T328 (Fig 6) . Furthermore, deletion of the last two Ser residues (mutant T348), including one PKC phosphorylation site in the receptor tail, prevented PMA-induced desensitization of the AT 1A -R by Ϸ30% (Fig 6) .
Biological Properties of WT and Truncated Mutants of Rat AT 1A -R Stably Expressed in CHO Cells
Phosphorylation of Thioredoxin-AT 1A Fusion Protein by PKC
To determine whether the cytoplasmic tail of AT 1A -R could be phosphorylated by PKC, we generated a thioredoxin fusion protein containing the entire carboxyl tail of the AT 1A -R ( Fig  7A) . The purified thioredoxin-AT 1A fusion protein was then used in an in vitro PKC phosphorylation assay. It was not a surprise that the thioredoxin-AT 1A fusion protein was highly phosphorylated by PKC (mixture of ␣, ␤, and ␥) (Fig 7B) , since there are three potential PKC phosphorylation sites in the carboxyl tail of the AT 1A -R. However, the thioredoxin-AT 1A fusion protein was not phosphorylated by Src kinase, even though a Src kinase substrate peptide (KVEKIGEGTYGV VKK) 21 was highly phosphorylated (205 728Ϯ17 235 cpm, 8-fold incorporation over background). There was no phosphorylation of the thioredoxin protein by PKC or Src kinase (Fig 7B) .
Ang II Did Not Induce Translocation of GRK2, GRK3, or GRK6
Agonist-induced translocation of GRK1, GRK2, or GRK3 is considered the first step involved in the homologous desensitization of rhodopsin or ␤-adrenergic receptors, respectively. 22 To determine whether Ang II could induce translocation of GRK from cytosol to the plasma membranes, CHO/AT 1A -R cells were pretreated with 1 mol/L PMA overnight to deplete PKC and then exposed to 100 nmol/L Ang II for 15 minutes. Plasma membranes were prepared, and the kinase activity associated with the membranes was determined using thioredoxin-AT 1A fusion protein as a substrate. As shown in Fig 7C, the phosphorylation of the thioredoxin-AT 1A fusion protein was increased dramatically by membranes derived from Ang II-treated CHO/AT 1A -R cells depleted of PKC. This indicated that the cytoplasmic tail of AT 1A -R could be phosphorylated by a PKC-independent mechanism. Moreover, the Ang II-induced kinase activity in the membrane fraction was completely inhibited by the GRK inhibitor heparin (100 nmol/L) (Fig 7C) but not by the PKC-specific inhibitor GF109203X or the PKA inhibitor H-89 (data not shown). To determine which individual GRK is selectively activated (by translocation) on Ang II stimulation, CHO/AT 1A -R cells or VSMCs were stimulated with Ang II for different time periods, and the cytosol and plasma membranes were prepared. Western blot experiments showed that GRK2 was almost equally distributed in cytosol or plasma membranes of the CHO/ AT 1A -R cells, whereas GRK3 was mainly present in cytosol (Fig 8A) . Ang II treatment did not induce translocation of GRK2 or GRK3 in CHO/AT 1A -R cells, since the protein level of GRK2 or GRK3 in the cytosolic and membrane fractions was not changed by Ang II stimulation (Fig 8A) . Similar results with GRK2 and GRK3 were obtained before and after Ang II treatment in VSMCs (data not shown). In addition, acute PMA treatment had no effect on the translocation of GRK2 or GRK3 in either CHO/AT 1A -R cells ( Fig  8A) or VSMCs (data not shown). However, translocation of GRK2 was observed by agonist UK14,304 treatment in MDCK cells stably expressing ␣ 2A -adrenergic receptors 23 ( Fig  8B) . GRK5 was undetectable in CHO/AT 1A -R cells but was detected in VSMCs (Fig 8C) . GRK6 was detected only in the plasma membranes of both CHO/AT 1A -R cells (Fig 8D) and VSMCs (not shown). The localization of GRK6 was not changed on Ang II stimulation of CHO/AT 1A -R cells (Fig 8D) or VSMCs (not shown). On the other hand, PKC was rapidly activated by Ang II in CHO/AT 1A -R cells as well as in VSMCs (not shown), as reported previously.
24,25
Discussion
In the present study, we have used four truncated mutants of AT 1A -R (T310, T318, T328, and T348) lacking the potential carboxyl-terminal phosphorylation sites but retaining the normal binding of Ang II intact. We showed that the proximal portion (K 310 to L 317 ) of the receptor cytoplasmic tail is involved in the AT 1A -R coupling to G q , whereas the middle portion (S 328 to S 347 ) containing the potential Ser/Thr (eight Ser and two Thr residues) phosphorylation sites plays an important role in the agonist-and PMA-induced desensitization of the AT 1A -R. Furthermore, the thioredoxin-AT 1A fusion protein containing the entire cytoplasmic tail of the AT 1A -R can be heavily phosphorylated by PKC and by a membrane-associated heparin-sensitive kinase from Ang IItreated CHO/AT 1A -R cells depleted of PKC.
It has been noted that Ang II action is accompanied by a rapid and profound desensitization known as tachyphylaxis. However, the mechanisms by which Ang II receptors desensitize are still not clear. It seems that receptor sequestration or internalization does not play a major role in causing the homologous desensitization of the AT 1A -R expressed in CHO cells, since the complete desensitization induced by 15 minutes of incubation with 100 nmol/L Ang II still occurred even when the receptor internalization was almost completely blocked by concanavalin A 2 or phenylarsine oxide treatment (loss of membrane receptors: 12Ϯ2% with concanavalin AϩAng II or 8Ϯ0.6% with phenylarsine oxideϩAng II versus 50Ϯ4% with Ang II alone). Similar findings have been reported for the AT 1 receptors in cardiomyocytes, 1 AT 1B -R expressed in CHO cells, 2 AT 1A -R expressed in 293 cells, 3 and other PLC-linked GPCRs. 26, 27 Thus, rapid desensitization of the AT 1A -R-mediated IP 3 formation may well be a consequence of the agonist-induced biochemical modification of the receptor, such as receptor phosphorylation.
The cytoplasmic tail of the AT 1A -R contains multiple Ser/Thr residues (13 of the last 59 amino acids), and there are three consensus PKC phosphorylation sites (S 331 TK, S 338 YR, and S 348 AK). 28, 29 Removal of all Ser/Thr residues in the tail (truncated mutant T318) or removal of all Ser/Thr residues but the S 326 (mutant T328) dramatically impaired agonist-and PMA-induced desensitization of the receptor. Deletion of the last two Ser residues, including one PKC consensus site, prevented only the PMA-induced heterologous desensitization by Ϸ30%, suggesting that two other PKC consensus sites (S 331 TK and S 338 YR) may chiefly contribute to the PKC- dependent desensitization of the AT 1A -R. Since the immunoprecipitable antibody against the AT 1 receptor is not available, we cannot measure the receptor phosphorylation on agonist or PMA stimulation. We made and prepared a purified thioredoxin-AT 1A fusion protein that contains the entire cytoplasmic tail of AT 1A -R. The thioredoxin-AT 1A fusion protein was highly phosphorylated by PKC and by a membrane-associated heparin-sensitive kinase from Ang II-treated CHO/AT 1A -R cells depleted of PKC, but not by Src kinase in vitro despite the presence of four tyrosine residues in the receptor cytoplasmic tail. Taken together, these results indicate that the phosphorylation of the receptor cytoplasmic tail is involved in the homologous and heterologous desensitization of the AT 1A -R and that the potential Ser/Thr phosphorylation sites important for the AT 1A -R desensitization are located between S 328 and S 347 (containing eight Ser and two Thr residues) of the receptor cytoplasmic tail. Studies are now in progress to identify the major phosphorylation site(s) by the agonist or PMA treatment.
The PKC-specific inhibitor GF109203X completely suppressed the desensitization of AT 1A -R by Ang II at a low concentration (1 nmol/L). This suggests that PKC plays a major role in heterologous desensitization at a near-physiological agonist concentration. The desensitizing effect at a higher agonist concentration (100 nmol/L) is only partially prevented by the inhibition of PKC. Previous studies have shown that the PKC inhibitor staurosporine suppressed agonist-induced Ang II receptor desensitization in Xenopus oocytes. 14 Pfeilschifter and coworkers 30 -32 have obtained evidence implicating PKC in the Ang II-induced desensitization in glomerular mesangial cells. We have demonstrated that PKC is only partially involved in agonist-induced desensitization of AT 1B -R in transfected CHO cells.
2 Similar findings have also been reported for several other PLC-linked GPCRs. 33, 34 In contrast, PKC depletion or treatment with the selective PKC inhibitor RO31-7519 did not affect the rapid agonist-induced desensitization of the Ang II receptor in neonatal cardiac myocytes. 1 Recently, Oppermann et al 3 reported that PKC inhibition with staurosporine reduced agonist-induced phosphorylation of AT 1A -R by 40% to 50% in transfected 293 cells but did not affect the agonist-induced desensitization of the receptor. In aggregate, these studies and ours suggest that the agonistinduced desensitization of AT 1A -R may only be partially regulated by PKC in a cell type-specific manner.
A wasp venom peptide, mastoparan, has been shown to mimic the agonist-bound (active form) GPCRs and activate GRKs. 17, 18 Challenging the permeabilized cells expressing WT AT 1A -R with mastoparan completely abolished the receptor-mediated IP 3 response to Ang II. Pretreatment of the permeabilized cells with the GRK inhibitor heparin largely prevented the agonist-induced desensitization of AT 1A -R. Furthermore, treatment of the cells depleted of PKC with Ang II induced the translocation of a heparin-sensitive kinase activity, which could phosphorylate the thioredoxin-AT 1A fusion protein containing the entire cytoplasmic tail of AT 1A -R. These data indicate that the heparin-sensitive kinase may be mainly involved in the agonist-induced homologous desensitization of AT 1A -R. Six members of the GRK family have been cloned to date 35 and, on the basis of structural similarities, have been divided into three subfamilies: (1) rhodopsin kinase (GRK1), (2) the ␤-adrenergic receptor kinase subfamily (GRK2 and GRK3), and (3) the GRK4 subfamily (GRK4, GRK5, and GRK6). GRKs also seem to have different patterns of expression in tissues. GRK1 and GRK4, for instance, are primarily expressed in retinal cells and testis, respectively, suggesting very specific functions. Whereas, other GRKs are expressed in many tissues, suggesting their broad roles in regulating the functions of GPCRs. Overexpression (Ͼ20-fold) of either GRK2, GRK3, or GRK5 was shown to enhance agonist-induced AT 1A -R phosphorylation equally well, 3 suggesting a role for GRKs (GRK2, GRK3, and GRK5) in the agonist-induced phosphorylation and desensitization of the AT 1A -R. Since active GPCRs (agonistbound form), in the presence of charged phospholipids, can directly associate with and activate GRKs, 36, 37 it is possible that overexpression (20-fold) of either GRK2, GRK3, or GRK5 could result in nonspecific direct interaction between Ang IIbound AT 1A -R with the overexpressed GRK, leading to the enhanced agonist-induced phosphorylation of AT 1A -R, since experiments did not show a significant difference between individual GRKs in their ability to enhance receptor phosphorylation in response to Ang II. 3 As described above, we have demonstrated that the cytoplasmic tail of AT 1A -R plays a critical role in the agonist-induced homologous desensitization of the receptor. The cytoplasmic tail of AT 1A -R does not contain the consensus phosphorylation sites for GRK1 (the presence of acidic residue on the C-terminal side of a Ser/Thr), GRK2, and GRK3 (the presence of acidic residue localized to the N-terminal side of a Ser/Thr). 37, 38 Stimulation of CHO/AT 1A -R cells or VSMCs with Ang II did not induce translocation of GRK2 and GRK3. GRK5 was not detected in CHO/AT 1A -R cells but was detected only in the membrane fraction of quiescent VSMCs. GRK6 was detected only in the plasma membranes of both CHO/AT 1A -R cells and VSMCs. The localization of GRK6 was not affected by Ang II stimulation of either CHO/AT 1A -R cells or VSMCs. Moreover, we immunoprecipitated GRK6 and measured its catalytic activity using a soluble GRK substrate, casein, according to method of Pitcher et al. 39 The activity of GRK6 was not affected by Ang II treatment in CHO/AT 1A -R cells (not shown). Therefore, it seems that GRK2, GRK3, or GRK6 might not be involved in the agonist-induced homologous desensitization of the AT 1A -R, at least in CHO/AT 1A -R cells and VSMCs. Recently, a novel heparin-sensitive 40-kD receptor kinase, designated as MEK, was purified from porcine cerebellum. It was identified in the CHO cells expressing the m3-muscarinic receptor, and the activity of MEK in the membrane fraction was increased after the agonist stimulation. 40 In summary, the data presented have demonstrated that potential Ser/Thr phosphorylation sites located between S 328 and S 347 in the cytoplasmic tail of AT 1A -R play a critical role in the heterologous and homologous desensitization of the receptor. Although a recent study 5 reported that the cytoplasmic tail of AT 1A -R is not involved in desensitization, the preliminary observation needs to be reconsidered, since no acidwashing step was taken to remove the receptor-bound Ang II before a second challenge of the cells with agonist during the measurement of Ca 2ϩ mobilization. However, the precise role played by the cytoplasmic tail of the AT 1A -R in the complex series of biochemical mechanisms underlying receptor regulation needs to be explored further. The present results with the
